Pioneer Research Solutions

Houston, Texas 77479

6 studies enrolling now · 32 studies all time

What they study most

Arthritis, Arthritis, Rheumatoid, Asthma, Cyclic Vomiting Syndrome, Diabetes Mellitus, Type 1, Difficult to Control Hypertension, Gout, Healthy Volunteers, Influenza, Insomnia, Irritable Bowel Syndrome, Liver Stiffness

Studies at this site

• A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants — Recruiting now
• A Study of Dotinurad Versus Allopurinol in Participants With Gout — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts — Recruiting now
• A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Recruiting now
• To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension — Recruiting now
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication — Completed
• A Study of Baricitinib in Participants With Rheumatoid Arthritis — Completed
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. — Running, not enrolling
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households — Completed
• Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome — Completed
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness — Completed
• Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) — Completed
• A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. — Completed
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus — Completed
• A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma — Completed
• Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients — Completed
• Tanezumab In Osteoarthritis Of The Hip Or Knee — Stopped early
• An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). — Completed
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• Tanezumab in Osteoarthritis Of The Hip — Completed
• A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis — Completed
• Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis — Completed
• Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro — Withdrawn before enrolling
• A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy — Stopped early
• A Study in Moderate to Severe Rheumatoid Arthritis — Completed
• A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma — Completed
• TC-6987 for the Treatment of Mild to Moderate Asthma — Completed
• Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome — Completed